a:5:{s:8:"template";s:12359:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="initial-scale=1, width=device-width" name="viewport"/>
<title>{{ keyword }}</title>
<link href="https://fonts.googleapis.com/css?family=Droid+Serif:400,400italic,700,700italic&amp;subset=latin%2Clatin-ext" id="wp-garden-droid-font-css" media="all" rel="stylesheet" type="text/css"/>
<link href="https://fonts.googleapis.com/css?family=Shadows+Into+Light&amp;subset=latin%2Clatin-ext" id="wp-garden-shadows-font-css" media="all" rel="stylesheet" type="text/css"/>
<link href="http://fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%2C300italic%2C400italic%2C600italic%2C700italic%2C800italic%7CRaleway%3A100%2C200%2C300%2C400%2C500%2C600%2C700%2C800%2C900&amp;ver=5.4" id="redux-google-fonts-smof_data-css" media="all" rel="stylesheet" type="text/css"/></head>
<style rel="stylesheet" type="text/css">@charset "UTF-8";.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal} html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}article,aside,footer,header,nav{display:block}a{background-color:transparent}a:active,a:hover{outline:0}/*! Source: https://github.com/h5bp/html5-boilerplate/blob/master/src/css/main.css */@media print{*,:after,:before{color:#000!important;text-shadow:none!important;background:0 0!important;-webkit-box-shadow:none!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}h3{orphans:3;widows:3}h3{page-break-after:avoid}} *{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:10px;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#337ab7;text-decoration:none}a:focus,a:hover{color:#23527c;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}h3{font-family:inherit;font-weight:500;line-height:1.1;color:inherit}h3{margin-top:20px;margin-bottom:10px}h3{font-size:24px}.text-left{text-align:left}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.row{margin-right:-15px;margin-left:-15px}.col-lg-3,.col-lg-6,.col-lg-9,.col-md-3,.col-md-6,.col-md-9,.col-sm-12,.col-sm-3,.col-sm-6,.col-sm-9,.col-xs-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}.col-xs-12{float:left}.col-xs-12{width:100%}@media (min-width:768px){.col-sm-12,.col-sm-3,.col-sm-6,.col-sm-9{float:left}.col-sm-12{width:100%}.col-sm-9{width:75%}.col-sm-6{width:50%}.col-sm-3{width:25%}}@media (min-width:992px){.col-md-3,.col-md-6,.col-md-9{float:left}.col-md-9{width:75%}.col-md-6{width:50%}.col-md-3{width:25%}}@media (min-width:1200px){.col-lg-3,.col-lg-6,.col-lg-9{float:left}.col-lg-9{width:75%}.col-lg-6{width:50%}.col-lg-3{width:25%}}.collapse{display:none}.navbar-collapse{padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;-webkit-box-shadow:inset 0 1px 0 rgba(255,255,255,.1);box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;-webkit-box-shadow:none;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.clearfix:after,.clearfix:before,.container:after,.container:before,.navbar-collapse:after,.navbar-collapse:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container:after,.navbar-collapse:after,.row:after{clear:both}@-ms-viewport{width:device-width}  body{font-family:'Open Sans';color:#767676;background-attachment:fixed;background-size:cover;background-position:center}a{color:#6f4792}a:hover{color:#6ab42f}article,aside,body,div,footer,h3,header,html,i,li,nav,span,ul{-moz-osx-font-smoothing:grayscale;text-rendering:optimizelegibility}#cshero-header-navigation{position:static}h3{margin:0 0 10px;line-height:1.8}#cshero-footer-top{padding:83px 0 81px}#cshero-footer-top .cms-recent-posts article{position:relative;margin-bottom:25px}#cshero-footer-top h3.wg-title{color:#fff;font-size:21px!important;font-weight:700;margin-bottom:30px!important}#cshero-footer-bottom{border-top:1px solid #333;color:#767676;padding:29px 0 28px;font-weight:600!important}#cshero-header{width:100%;position:relative}#cshero-header nav.main-navigation ul.menu-main-menu>li>a{line-height:103px}#cshero-header-top{background-color:#6ab42f}#cshero-header{height:103px;background-color:#fff}#cshero-header #cshero-header-logo a{line-height:103px;-webkit-transition:line-height .4s ease-in-out;-khtml-transition:line-height .4s ease-in-out;-moz-transition:line-height .4s ease-in-out;-ms-transition:line-height .4s ease-in-out;-o-transition:line-height .4s ease-in-out;transition:line-height .4s ease-in-out}#cshero-header #cshero-header-logo a:focus{outline:0}#cshero-header #cshero-header-navigation{-webkit-transition:line-height .1s ease-in-out;-khtml-transition:line-height .1s ease-in-out;-moz-transition:line-height .1s ease-in-out;-ms-transition:line-height .1s ease-in-out;-o-transition:line-height .1s ease-in-out;transition:line-height .1s ease-in-out}#cshero-header #cshero-header-navigation nav#site-navigation{float:right}#cshero-header #cshero-header-navigation nav#site-navigation ul#menu-primary-menu>li>a{color:#222}#cshero-header #cshero-header-navigation nav#site-navigation ul#menu-primary-menu>li>a span{padding:7.7px 15px}#cshero-header #cshero-header-navigation nav#site-navigation ul#menu-primary-menu>li>a:hover{color:#fff}#cshero-header #cshero-header-navigation nav#site-navigation ul#menu-primary-menu>li>a:hover span{background-color:#6ab42f}#cshero-header #cshero-header-navigation nav#site-navigation ul#menu-primary-menu>li>a:focus{outline:0;text-decoration:none}#cshero-header #cshero-menu-mobile i{display:none}@media screen and (max-width:991px){#cshero-header{height:60px}#cshero-header #cshero-header-logo a{line-height:60px}#cshero-header #cshero-menu-mobile{float:right;position:absolute;right:15px;top:50%;-webkit-transform:translatey(-50%);-khtml-transform:translatey(-50%);-moz-transform:translatey(-50%);-ms-transform:translatey(-50%);-o-transform:translatey(-50%);transform:translatey(-50%)}#cshero-header #cshero-menu-mobile i{display:block!important;padding:0 0 0 30px}}@media screen and (min-width:992px){#cshero-header-navigation .main-navigation ul{margin:0;text-indent:0}#cshero-header-navigation .main-navigation li a{border-bottom:0;white-space:nowrap}#cshero-header-navigation .main-navigation .menu-main-menu>li{vertical-align:top}#cshero-header-navigation .main-navigation .menu-main-menu>li>a{position:relative;text-align:center;line-height:1.1;-webkit-transition:all .4s ease 0s;-khtml-transition:all .4s ease 0s;-moz-transition:all .4s ease 0s;-ms-transition:all .4s ease 0s;-o-transition:all .4s ease 0s;transition:all .4s ease 0s}#cshero-header-navigation .main-navigation .menu-main-menu>li:last-child>a{padding-right:0}#cshero-header-navigation .main-navigation .menu-main-menu>li,#cshero-header-navigation .main-navigation .menu-main-menu>li a{display:inline-block;text-decoration:none}}@media screen and (max-width:991px){.cshero-main-header .container{position:relative}#cshero-menu-mobile{display:block}#cshero-header-navigation{display:none}#cshero-menu-mobile{display:block}#cshero-menu-mobile i{color:inherit;cursor:pointer;font-size:inherit;line-height:35px;text-align:center}#cshero-header #cshero-header-navigation .main-navigation{padding:15px 0}#cshero-header #cshero-header-navigation .main-navigation .menu-main-menu li{line-height:31px}#cshero-header #cshero-header-navigation .main-navigation .menu-main-menu li a{background:0 0;color:#fff}#cshero-header-navigation .main-navigation .menu-main-menu>li{position:relative}#cshero-header-navigation .main-navigation .menu-main-menu>li a{display:block;border-bottom:none;font-size:14px;color:#222}}@media screen and (max-width:991px){#cshero-footer-bottom .footer-bottom-widget{text-align:center}#cshero-footer-top .widget-footer{height:270px;margin-bottom:40px}}@media screen and (max-width:767px){#cshero-footer-top .widget-footer{padding-top:40px}}.container:after,.navbar-collapse:after,.row:after{clear:both}.container:after,.container:before,.navbar-collapse:after,.navbar-collapse:before,.row:after,.row:before{content:" ";display:table}.vc_grid.vc_row .vc_pageable-slide-wrapper>:hover{z-index:3} @font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFVZ0e.ttf) format('truetype')} @font-face{font-family:Raleway;font-style:normal;font-weight:400;src:local('Raleway'),local('Raleway-Regular'),url(http://fonts.gstatic.com/s/raleway/v14/1Ptug8zYS_SKggPNyC0ISg.ttf) format('truetype')}@font-face{font-family:Raleway;font-style:normal;font-weight:500;src:local('Raleway Medium'),local('Raleway-Medium'),url(http://fonts.gstatic.com/s/raleway/v14/1Ptrg8zYS_SKggPNwN4rWqZPBQ.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:500;src:local('Roboto Medium'),local('Roboto-Medium'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmEU9fBBc9.ttf) format('truetype')} @font-face{font-family:Raleway;font-style:normal;font-weight:500;src:local('Raleway Medium'),local('Raleway-Medium'),url(http://fonts.gstatic.com/s/raleway/v14/1Ptrg8zYS_SKggPNwN4rWqZPBQ.ttf) format('truetype')}</style>
<body class="wpb-js-composer js-comp-ver-4.10 vc_responsive">
<div class="" id="page">
<header class="site-header" id="masthead">
<div id="cshero-header-top" style="display:">
<div class="container">
<div class="row">
</div>
</div>
</div>
<div class="cshero-main-header no-sticky " id="cshero-header">
<div class="container">
<div class="row">
<div class="col-xs-12 col-sm-3 col-md-3 col-lg-3" id="cshero-header-logo">
<a href="#">{{ keyword }}</a>
</div>
<div class="col-xs-12 col-sm-9 col-md-9 col-lg-9 megamenu-off" id="cshero-header-navigation">
<nav class="main-navigation" id="site-navigation">
<div class="menu-primary-menu-container"><ul class="nav-menu menu-main-menu" id="menu-primary-menu"><li class="menu-item menu-item-type-custom menu-item-object-custom menu-item-home menu-item-1276" id="menu-item-1276"><a href="#"><span>Home</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1437" id="menu-item-1437"><a href="#"><span>Our Services</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1456" id="menu-item-1456"><a href="#"><span>About us</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1278" id="menu-item-1278"><a href="#"><span>Blog</span></a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-page menu-item-1325" id="menu-item-1325"><a href="#"><span>Contact</span></a></li>
</ul></div> </nav>
</div>
<div class="collapse navbar-collapse" id="cshero-menu-mobile"><i class="fa fa-bars"></i></div>
</div>
</div>
</div>
 </header>
<div id="main">
{{ text }}
</div>
<footer>
<div id="cshero-footer-top">
<div class="container">
<div class="row">
<div class="col-xs-12 col-sm-6 col-md-3 col-lg-3 widget-footer"><aside class="widget cms-recent-posts" id="cms_recent_posts-4"><h3 class="wg-title">Recent Posts</h3> <article class="recent-post-item clearfix post-890 post type-post status-publish format-standard has-post-thumbnail hentry category-lawn-maintenance tag-lawn-care">
{{ links }}
</article>
</aside></div>
</div>
</div>
</div>
<div id="cshero-footer-bottom">
<div class="container">
<div class="row">
<div class="col-xs-12 col-sm-12 col-md-6 col-lg-6 footer-bottom-widget text-left">{{ keyword }} 2021</div>
</div>
</div>
</div>
</footer>
</div>
</body></html>";s:4:"text";s:11719:"Patients taking denosumab not only had fewer bone complications, but they took longer to develop compared with Zometa, reported researchers of a phase 3 study presented Thursday at the San Antonio Breast Cancer Symposium. Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. Synopsis: Denosumab is more effective than zoledronic acid at preventing pain in women with advanced breast cancer and bone metastases. Denomsumab 120 mg subcutaneously with intravenous zoledronic acid placebo once every 4 weeks. Zometa also is used to lower their risk of a skeletal-related event. We evaluated further results from this study related to skeletal … (24) 2010 Multi- center (USA) RCT Phase III Breast Cancer 56 (49-65) Female 34 months Zoledronic Acid 4 mg 4 weeks I.V. J Clin Oncol 2003; 21: 3150 – 3157. a drug that’s given to reduce the risk of breast cancer spreading to the bones and other parts of the body. Abstract. Zometa (chemical name: zoledronic acid) is used to strengthen bones in women diagnosed with metastatic breast cancer that has spread to the bones. Group 1 had denosumab as an injection into the skin, and a dummy drug through a drip into a vein Denosumab and zoledronic acid are both bone-modifying agents that prevent the occurrence of SREs. 1 However, to our knowledge, an OS benefit has not been demonstrated with denosumab in MM thus far. Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones. Effect of denosumab versus zoledronic acid treatment in patients with breast cancer and bone metastases: … They found that denosumab had a similar safety profile to zoledronic acid without any additional adverse effects. Amgen Inc., Thousand Oaks, Calif) with zoledronic acid (Zometa;Novartis,EastHanover,NJ),denosumabwas superior in preventing SREs among patients with breast cancer and bone metastases.10 Here, we report the effect of denosumab versus zoledronic acid on pain outcomes from that study, including pain severity,paininterference(ie,the J Natl Compr Canc Netw 2010; 8:279. Valachis A, Polyzos NP, Coleman RE, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study Denosumab was superior to zoledronic acid in delaying or preventing SREs in patients with breast cancer metastatic to bone and was generally well tolerated. [Google Scholar] In a randomized, phase 3 trial of 1,776 patients with metastases from solid tumors (except breast or prostate) or multiple myeloma, denosumab was non-inferior to zoledronic acid (ZA) in delaying or preventing SREs. Methods: Eligible studies included randomized studies evaluating adjuvant immediate denosumab or immediate zoledronic acid versus delayed treatment for patients with postmenopausal early breast cancer … A new drug called denosumab may soon give Zometa (zoledronic acid) competition as the standard of care in treating bone metastases in patients with advanced breast cancer. Rosen, LS, Gordon, D, Tchekmedyian, S, et al. Bone complications of metastatic disease, including skeletal-related events (SREs), impair patients' functioning and quality of life. Background: Denosumab is a fully human monoclonal antibody which inhibits RANKL, a key mediator of osteoclast activity. … doi: 10.1200/JCO.2010.31.3304. J Clin Oncol 29:1125–1132. Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer receiving subcutaneous denosumab 120 mg … Actual Study Start Date : June 1, 2006: Actual Primary Completion Date : April 1, 2009: Actual Study Completion Date : XGEVA ® (DENOSUMAB) HAS PROVEN SUPERIORITY OVER ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL-RELATED EVENTS (SRE s) IN PATIENTS WITH BONE METASTASES FROM BREAST AND CASTRATION-RESISTANT PROSTATE CANCER, REDUCING THE RISK OF DEVELOPING THE FIRST ON-STUDY SRE BY 18% COMPARED WITH ZOLEDRONIC ACID. With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases. Zoledronic acid 4 mg by intravenous... Denomsumab 120 mg subcutaneously wi... Arm/Group Description. Henry DH, Costa L, Goldwasser F et al (2011) Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. MRONJ induced by denosumab VS. zoledronic acid Author Year Country Study design Phase Population Mean age Gender Follow up Drugs Dose Frecuency of adminis - tration Route of adminis-tration Stopeck et al. 1125 - 1132 Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. One study by Choi et al. 2012;48(16):3082-3092. Results from the primary analysis of this pivotal phase 3 trial showed that denosumab was superior to zoledronic acid (ZA) in delaying the time to first on-study skeletal-related events (SRE) in patients with breast cancer and bone metastases. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Zoledronic acid 4 mg by intravenous injection with subcutaneous denosumab placebo once every 4 weeks. Arm/Group Description. Thus, several guidelines have included zoledronic acid and clodronic acid as adjuvant treatments for breast cancer in postmenopausal women. This study aims to assess the cost-effectiveness of denosumab vs. zoledronic acid in the prevention of SREs in patients with advanced breast cancer and bone metastases. This study is one of three virtually identical trials comparing denosumab with zoledronic acid. Stopeck A, Martin M, Ritchie D, et al. Creation of a standard test for MAF amplification status could be clinically helpful to exclude premenopausal patients with early breast cancer from receiving zoledronic acid and potentially other bisphosphonates. How MAF status might inform the use of denosumab in this setting remains uncertain. The primary hypothesis was that treatment with denosumab was not inferior to zoledronic acid for the mean percentage change from baseline in lumbar spine BMD at month 12 based on a margin of -0.46%; Secondary hypotheses included the following: noninferiority in total hip BMD with denosumab vs zoledronic acid based on a margin of -0.51% Stopeck AT, Lipton A, Body J-J, et al. The aim of this trial was to find out whether denosumab worked as well as zoledronic acid for cancer that had spread to the bones. compared the safety profiles of denosumab and zoledronic acid in osteoporosis, irrespective of the cause. XGEVA ® (denosumab) prescribing information, Amgen. Henry DH, Costa L, Goldwasser F, et al. Eur J Cancer. A meta-analysis of randomized controlled trials. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. interfere with the breakdown of bone tissue that results when cancer cells form metastases in the bone. The research team found that denosumab was better than zoledronic acid for preventing bone problems in people with breast cancer that had spread to the bone.  There are not many safety comparison studies for these two drugs in our population group. Denosumab was superior to zoledronic acid in delaying or preventing SREs in patients with breast cancer metastatic to bone and was generally well tolerated. A post hoc analysis of the ‘482 study 1 demonstrated a PFS benefit of denosumab over zoledronic acid, with an absolute benefit of 10.7 months and an HR of 0.82 (95% CI, 0.68-0.99; P = .04). 2010;28(35):5132-5139. Denosumab prevented more events, was better tolerated, and was more convenient for breast cancer patients with skeletal metastasis, according to results from a randomized double-blind trial that matched the RANK ligand inhibitor against zoledronic acid. The first phase III trial to compare directly denosumab to zoledronic acid in patients with metastatic breast cancer had a total of 2,046 biphosphonate naive patients (except treatment with oral bisphosphonates for osteoporosis). 1. In this study, the authors evaluated the effect of denosumab versus zoledronic acid (ZA) on pain in patients with advanced breast cancer and bone metastases. 2012;48(16):3082-3092. Published on November 9, 2010 at 12:00 AM. J Clin Oncol. This phase 3 trial recruited 2,046 people with breast cancer into one of two groups. Denosumab is a type of biological therapy called a monoclonal antibody. Denosumab has been shown to be superior to zoledronic acid in delaying SREs in various types of cancer, such as breast cancer, lung cancer, and multiple myeloma. Lipton A, Fizazi K, Stopeck AT, et al. The study also compared monthly denosumab to monthly zoledronic acid. A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Eur J Cancer. J Clin Oncol. Materials and methods A Markov model was developed with 4-week model cycles and a 1-year time horizon. A randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol , 29 ( 9 ) ( 2011 ) , pp. Patients and Methods Eligible patients were randomly assigned in a double … Soluble receptor activator of nuclear factor κB Fc diminishes prostate cancer progression in bone. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. including for prevention of bone metastases. Data on file, Amgen. ABSTRACTBackground: A mixed treatment analysis of the comparative effectiveness of denosumab versus zoledronic acid in the prevention of fractures in early postmenopausal breast cancer patients treated with aromatase inhibitors has been conducted.Methods: Eligible studies included randomized studies evaluating adjuvant immediate denosumab or immediate zoledronic acid versus … Purpose. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. XGEVA ® (denosumab) prescribing information, Amgen. Denosumab was superior to zoledronic acid in reducing bone-related complications of metastatic breast cancer and maintained health-related quality of life, according to results of a … Background: A mixed treatment analysis of the comparative effectiveness of denosumab versus zoledronic acid in the prevention of fractures in early postmenopausal breast cancer patients treated with aromatase inhibitors has been conducted. Denosumab prolonged the time to … Patients received denosumab 120 mg or zoledronic acid … In a systematic review of comparative trials, denosumab was superior to zoledronic acid in delaying SREs in patients with breast or prostate cancer who had bone metastases (Table 2). ";s:7:"keyword";s:42:"denosumab vs zoledronic acid breast cancer";s:5:"links";s:1338:"<a href="http://truck-doctor.com/e590c6p/pop-culture-store-opry-mills">Pop Culture Store Opry Mills</a>,
<a href="http://truck-doctor.com/e590c6p/farmington-country-club">Farmington Country Club</a>,
<a href="http://truck-doctor.com/e590c6p/hyatt-regency-thrissur-food-menu">Hyatt Regency Thrissur Food Menu</a>,
<a href="http://truck-doctor.com/e590c6p/cookout-gift-cards-walmart">Cookout Gift Cards Walmart</a>,
<a href="http://truck-doctor.com/e590c6p/montevideo-convention-palestine">Montevideo Convention Palestine</a>,
<a href="http://truck-doctor.com/e590c6p/dublin-airport-new-runway-construction">Dublin Airport New Runway Construction</a>,
<a href="http://truck-doctor.com/e590c6p/how-much-does-plato%27s-closet-pay">How Much Does Plato's Closet Pay</a>,
<a href="http://truck-doctor.com/e590c6p/racs-position-statements">Racs Position Statements</a>,
<a href="http://truck-doctor.com/e590c6p/district-of-massachusetts-cm-ecf-administrative-procedures">District Of Massachusetts Cm Ecf Administrative Procedures</a>,
<a href="http://truck-doctor.com/e590c6p/hdpe-pipe-jointing-heater">Hdpe Pipe Jointing Heater</a>,
<a href="http://truck-doctor.com/e590c6p/ramiel-angel-evangelion">Ramiel Angel Evangelion</a>,
<a href="http://truck-doctor.com/e590c6p/girvan-newman-algorithm-complexity">Girvan-newman Algorithm Complexity</a>,
";s:7:"expired";i:-1;}